Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT Study)

CMAJ. Canadian Medical Association Journal

Volumn 155, Issue 9, 1996, Pages 1251-1259

  Nickel, J Curtis ^a,h   Fradet, Yves ^b   Boake, Rex C ^c   Pommerville, Peter J ^d   Perreault, Jean Paul ^e   Afridi, Salim K ^f   Elhilali, Mostafa M ^g  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d VICTORIA GENERAL HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Saskatoon Health Region St Pauls Hospital   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; URINE FLOW RATE;

EID: 0029827421     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McNeal JE. Morphology and biology of benign prostatic hyperplasia. In: Bruckovsky N, Chapdelaine A, Neumann F, editors. Regulation of androgen action. Proceedings of an international symposium, Montreal 1984. Berlin: R. Bruckner, 1985:23-30.
2. Boyarsky S, Jones G, Paulson D, et al. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1977;68:29-32.
3. Turner-Warwick R, Whiteside C, Arnold E, et al. A urodynamic view of prostatic obstruction and the results of prostatectomy. Br J Urol 1973;45:631-45.
4. Barry M, Cockett A, Holtgrewe H, et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-8.
5. McConnell J, Barry M, Bruskewitz R, et al: Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline no 8. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Feb 1994. AHCPR Pub no 94-0582.
6. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. J Urol 1996;155:595-600.
7. Girman CJ, Epstein RS, Jacobsen SJ, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994;44:825-31.
8. Wasson J, Reda D, Bruskewitz M, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75-9.
9. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy, immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
10. Hieble J, Boyce A, Caine M. Comparison of the alpha adrenoceptor characteristics in human and canine prostate. Fed Proc 1986;45:2609-14.
11. Elhilali MM, Ramsey EW, Barkin J, et al. A multicentre, randomized, double- blind, placebo-controlled study to evaluate the safety and efficacy of terazocin in the treatment of benign prostatic hyperplasia. Urology 1996;47:335-42.
12. Stoner E. Finasteride study group: maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 1994;154:83-8.
13. Hunter HJ. Observations on certain parts of the animal oeconomy. Philos Trans R Soc London 1786;4:31-46.
14. Walsh P, Madden J, Harrod M, et al. Familial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974;291:944-9.
15. Bruchovsky N, Wilson J. The conversion of testosterone to 5-alpha-androstane-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-21.
16. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992;22:271-7.
17. Gormley GJ, Stoner E, Bruskewik RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91.
18. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-94.
19. Bolognese J, Kozloff R, Kunik S, et al. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 1992;21:291-9.
20. Fisher LD, Dixon DO, Herson J, et al. Intention to treat in clinical trials. In: Peace KE, editor. Statistical issues in drug research and development. New York: Marcel Dekker Inc., 1990:331-50.
21. Andersen J, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995;46:631-7.